Abstract
Designing new-type nanosystems to realize the combination of multiple treatment is an efficient routine to enhance the anti-tumor efficacy in clinic. In this study, molybdenum disulfide (MoS2) was selected as a photothermal agent, and mesoporous silica (mSiO2) was coated on the surface of MoS2 using the solvothermal and template removal methods. The chemotherapeutic drug doxorubicin hydrochloride (DOX) as a model drug was then loaded into the above MoS2@mSiO2 nanocarrier to prepare the tumor-targeting MoS2@mSiO2-DOX nanosystem. XRD, UV–Vis, FTIR, SEM, TEM, and DLS results jointly confirmed that the MoS2@mSiO2-DOX nanosystem with a particle size of approximately 370 nm was successfully synthesized. The XPS and BET analysis identified that the outer layer of MoS2@mSiO2 nanocarrier was SiO2, which has a large surface area of 99.41 m2/g with an average pore size of 3.5 nm coated on the MoS2. The in-vitro cytotoxicity and photothermal performance of the MoS2@mSiO2 nanodrug delivery system was tested, and the results show that MoS2@mSiO2 has a low toxicity to normal human liver cells (HL-7702), and which also exhibits a good photothermal stability with a photothermal conversion efficiency of 28.8%. With the aid of the large specific surface area of mSiO2 and the opposite zeta potential, a high amount of DOX was loaded on MoS2@mSiO2 nanocarrier, and the measured loading efficiency of DOX can reach up to 48.87%. The 48 h-drug release rate of MoS2@mSiO2-DOX reaches 35.65% under the conditions of near infrared (NIR) laser irradiation at pH=5.0, which is nearly 5 times higher than that of 6.26% under the normal physiological environment (pH=7.4 without NIR laser irradiation), indicating that the MoS2@mSiO2-DOX nanosystem possesses obvious pH and NIR laser responsive release characteristics. The MoS2@mSiO2 nanocarrier has good cytocompatibility, outstanding photothermal conversion and drug loading properties, and after DOX adsorption, the system exhibits excellent pH and laser responsive drug controlled release performance, which is expected to be widely used in the field of combining the photothermal-chemotherapy to synergistically resist tumor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
